FDA Approves Merck’s Keytruda Combo For Esophageal Carcinoma

FDA approved Merck Sharp & Dohme Corp.’s pembrolizumab (Keytruda) in combination with platinum and fluoropyrimidine-based chemotherapy for certain patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma.

• Recommended pembrolizumab dose for esophageal cancer is 200 mg every 3 weeks or 400 mg every 6 weeks

To view the source of this information click here

To contact the reporter on this story:
Linly Lin in San Francisco at llin153@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2021 Bloomberg L.P. All rights reserved. Used with permission.